Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Intangibles (2017 - 2021)

Avalo Therapeutics (AVTX) has disclosed Intangibles for 5 consecutive years, with $38000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Intangibles fell 97.6% year-over-year to $38000.0, compared with a TTM value of $38000.0 through Dec 2021, down 97.6%, and an annual FY2021 reading of $38000.0, down 97.6% over the prior year.
  • Intangibles was $38000.0 for Q4 2021 at Avalo Therapeutics, down from $304000.0 in the prior quarter.
  • Across five years, Intangibles topped out at $33.1 million in Q1 2018 and bottomed at $38000.0 in Q4 2021.
  • Average Intangibles over 5 years is $12.6 million, with a median of $2.4 million recorded in 2019.
  • Peak annual rise in Intangibles hit 29.0% in 2021, while the deepest fall reached 97.6% in 2021.
  • Year by year, Intangibles stood at $17.7 million in 2017, then crashed by 78.68% to $3.8 million in 2018, then crashed by 35.57% to $2.4 million in 2019, then tumbled by 34.67% to $1.6 million in 2020, then plummeted by 97.6% to $38000.0 in 2021.
  • Business Quant data shows Intangibles for AVTX at $38000.0 in Q4 2021, $304000.0 in Q3 2021, and $732000.0 in Q2 2021.